Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Purpura, Thrombocytopenic, Idiopathic 3Lymphoma 3Pheochromocytoma 1Ovarian Neoplasms 1Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 13Etoposide 10Prednisone 8Doxorubicin 8Whole-Body Irradiation 7Vincristine 7Rituximab 7Peripheral Blood Stem Cell Transplantation 7Melphalan 7Brentuximab Vedotin 7romidepsin 6fludarabine phosphate 6Mycophenolic Acid 6fludarabine 5Lenalidomide 5Gemcitabine 5Cytarabine 510-propargyl-10-deazaaminopterin 5Tacrolimus 4Granulocyte Colony-Stimulating Factor 4Carmustine 4Busulfan 4Antilymphocyte Serum 4pembrolizumab 3etoposide phosphate 3carmustine, poliferprosan 20 drug combination 3Vorinostat 3Sirolimus 3Nivolumab 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, T-Cell × fostamatinib × Clear all
NCT00798096 2016-09-19

Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma

Rigel Pharmaceuticals

Phase 2 Completed
18 enrolled 8 charts
Lymphoid

Lymphoma, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡